Business Development

Mitochondria are factories of energy that generate ATP and sustain life. Less is known about their role as a signaling apparatus that promote health and induce cell death when necessary. Damage to mitochondria leads to loss of energy, accumulation of misfolded proteins and aggregates that in turn de-polarize mitochondria and further loss of ATP and ultimately cell death. Due to high metabolic demand, neurons and especially dopaminergic regions of the brain are especially susceptible to mitochondrial damage. Gradual decline in neuronal function takes place beyond age 40 years, if mitochondrial damage is not repaired the aging process exacerbates. Insomnia, memory loss, cognition and neurodegeneration are signs of poor mitochondrial function in the brain. The role of healthy mitochondria is vital to prevent neurodegeneration. Myto Health nutraceuticals and small molecules are studied by many labs around USA to establish it role in preventing Alzheimer’s and Parkinson’s disease (AD and PD) models. Mitochondria is also a lifeline for muscle function. To that end its role in the heart and skeletal muscle is critical. At Myto Health we are working to validate small molecules that prevent heart attacks and promote rapid recovery from ischemia in animal models. High lipid load in obesity damages mitochondria, healthy mitochondria metabolize lipid content, reduces reactive oxygen, and promotes healthy aging. Thus, the role of healthy mitochondria is bedrock for good health and healthy aging.

Myto Health Business Model

At Myto health we believe that mitochondrial health is central to human health and disease of aging. We have established a multiprong therapeutic, consumer health (nutraceuticals) and personalized medicine business model. Myto Health will be successful by establishing partnership, collaboration and commercialization of its technologies. Myto Health has established a platform that is the source of many of the technologies and solutions discussed above. The main premise of Myto Health is that Ubiquitin Proteasome System (UPS) is the central machine that drives many parts of cells such as mitochondrial health. Aggregation of misfolded proteins that cause mitochondrial dysfunction must be removed by UPS. Damaged mitochondrial signals are first recognized by UPS that build poly-ubiquitin chains on mitochondrial proteins and induce mitophagy to remove damaged mitochondria. Induction of ubiquitin E3 ligases degrade repressor proteins that activate a global transcription factor, PGC1, that is responsible for transcribing mitochondrial genes and promote mitochondrial genes and promote mitobiogenesis.

Myto Health technology engine is driven by collection of tools to discover drugs and nutraceuticals and blood-based diagnostic biomarkers for aging and neurodegeneration by interrogating ubiquitin pathway enzymes such as ubiquitin ligases. Poly-ubiquitination of proteins is a code that is not completely understood. For example, building lysine 6 linked chain on mitochondrial proteins initiates mitophagy. Building of K63 poly-ubiquitin chains initiates autophagy, building lysine 48 linked poly-ubiquitin chains removes misfolded or aggregated proteins by proteasome and so on. Myto Health has developed numerous assays for ligases and poly-ubiquitin chains selective affinity matrices to address multiple areas and develop blood-based diagnostic biomarkers. Myto Health screened natural products libraries against ubiquitin ligases to discover nutraceuticals. Rationale designs of small molecules have helped discover E3 ligase(s) activators that promote mitophagy and mitobiogenesis. We believe these molecules have multi-indication properties. The blood-based diagnostic signatures of poly-ubiquitins will have broad diagnostic applications for early detection of Parkinson’s disease as well as other aging markers. Because of the breadth and depth of the platform translation of these products and services into clinic requires highly accomplished teams. Myto Health plans to share, partner, establish joint ventures, license, and seek investments to bring these technologies to patients and consumers.Myto Health invites inquiries from collaborators, investors, and organizations to explore these technologies to bring to market pace and ultimately benefit the patients. We are particularly interested in sharing the following technologies:

Blood-based ubiquitin signature for diagnosis of Parkinson’s disease

The diagnostic test has been validated with patients that have mutations in genes that lead to PD. Application of this test for late onset of PD diagnosis includes up to one million patients in the USA alone. Currently there is no blood-based test for diagnosis of PD.

Nutraceuticals that promote mitophagy and mitobiogenesis.

By screening ubiquitin ligases that activate mitophagy and consequently mitobiogenesis we have discovered nutraceuticals that promote these functions. Natural products can be marketed without FDA approval due to “GRAS” (acronym Generally Recognized As Safe). Under sections 201(s) and 409 of the Federal Food, Drug, and Cosmetic Act, any substance that is intentionally added to food is a food additive.

Rational designed small molecule to activate mitophagy and mitobiogenesis.

Keeping in mind that aging and neurodegeneration go hand in hand and ubiquitin proteasome system is the guardian of cellular health. Maintaining good mitochondrial health is key to good health. Dysfunction of mitochondria increases along with age. For many chronic diseases the root cause is mitochondrial dysfunction, such as AD, PD, memory, cognition, metabolic diseases and so on. To address these poly-indication maladies we have screened small molecule libraries against ubiquitin ligases that promote mitophagy and mitobiogenesis to elevate these diseases. Further medicinal chemistry of these molecules has improved potency and exposure on target tissues (brain). These molecules promote mitophagy and improve recovery from ischemic attack. Myto Health has elucidated detailed mechanism of action for the small molecules.
Please connect with bd@mytohealth.net

Contact: Sarah Thomas
Business Development Manager
Myto Health LLC
bd@mytohealth.net
www.mytohealth.net
Phone: (610) 644-6974 EXT 301